Éric Assenat

1.7k total citations
18 papers, 167 citations indexed

About

Éric Assenat is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Éric Assenat has authored 18 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 11 papers in Hepatology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Éric Assenat's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Éric Assenat is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Éric Assenat collaborates with scholars based in France, United States and Spain. Éric Assenat's co-authors include Boris Guiu, Carole Allimant, Donatella Marino, Peter Vogel, Takeshi Satoh, Shukui Qin, T Meyer, Serge Aho, RS Finn and Masashi Kudo and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Éric Assenat

14 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Éric Assenat France	7	113	83	46	40	32	18	167
Dongbo Xu China	5	115 1.0×	36 0.4×	41 0.9×	43 1.1×	56 1.8×	22	176
Santhalingam Jegatheeswaran United Kingdom	6	134 1.2×	162 2.0×	16 0.3×	58 1.4×	69 2.2×	9	240
Kenichiro Kodama Japan	8	135 1.2×	61 0.7×	55 1.2×	42 1.1×	21 0.7×	13	194
Derek-Zhen Xu China	5	124 1.1×	91 1.1×	31 0.7×	28 0.7×	22 0.7×	6	171
Katharina Joechle United States	11	106 0.9×	126 1.5×	42 0.9×	83 2.1×	156 4.9×	23	270
Magdalena Żotkiewicz United States	3	91 0.8×	68 0.8×	37 0.8×	36 0.9×	65 2.0×	7	162
Wenchang Yu China	8	113 1.0×	35 0.4×	34 0.7×	46 1.1×	40 1.3×	23	166
Iain Tan Singapore	5	128 1.1×	60 0.7×	130 2.8×	24 0.6×	23 0.7×	5	204
Joseph Hreiki United States	5	66 0.6×	74 0.9×	39 0.8×	21 0.5×	44 1.4×	6	159
Jasmine J. Wang United States	6	87 0.8×	51 0.6×	80 1.7×	35 0.9×	49 1.5×	9	209

Countries citing papers authored by Éric Assenat

Since Specialization

Citations

This map shows the geographic impact of Éric Assenat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Assenat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Assenat more than expected).

Fields of papers citing papers by Éric Assenat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Assenat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Assenat. The network helps show where Éric Assenat may publish in the future.

Co-authorship network of co-authors of Éric Assenat

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Assenat. A scholar is included among the top collaborators of Éric Assenat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Assenat. Éric Assenat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Merle, P., Julien Edeline, Karine Le Malicot, et al.. (2025). 1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC. Annals of Oncology. 36. S822–S822.

Bourien, Héloïse, Xavier Adhoute, Boris Campillo‐Gimenez, et al.. (2025). A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data. Digestive and Liver Disease. 57(10). 2011–2015.

Faure, Stéphanie, Marie Dupuy, Dominique Larrey, et al.. (2024). Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM. Alimentary Pharmacology & Therapeutics. 60(11-12). 1561–1572. 6 indexed citations

Garin, Étienne, Lambros Tselikas, Boris Guiu, et al.. (2024). Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial. Journal of Nuclear Medicine. 65(2). 264–269. 16 indexed citations

Mazard, Thibault, Caroline Mollévi, Evelyne M. Loyer, et al.. (2024). Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial. Cancer Imaging. 24(1). 77–77.

Assenat, Éric, Méher Ben Abdelghani, Hervé Perrier, et al.. (2023). LEANOX: Lean body mass normalization of oxaliplatin-based chemotherapy for patients with stage III colon cancer treated in adjuvant setting: Impact on oxaliplatin-induced sensitive neurotoxicity—A multicenter phase II randomized trial.. Journal of Clinical Oncology. 41(4_suppl). 92–92.

Qin, Shukui, Masashi Kudo, T Meyer, et al.. (2022). LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Annals of Oncology. 33. S1402–S1403. 54 indexed citations

Assenat, Éric, Emmanuelle Samalin, Thibault Mazard, et al.. (2022). Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.. Journal of Clinical Oncology. 40(16_suppl). TPS4190–TPS4190. 1 indexed citations

Edeline, Julien, Philippe Merle, Weijia Fang, et al.. (2022). Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.. Journal of Clinical Oncology. 40(16_suppl). 4072–4072. 2 indexed citations

10.

Delaye, Matthieu, Éric Assenat, Laëtitia Dahan, et al.. (2022). Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study.. Journal of Clinical Oncology. 40(16_suppl). 4108–4108. 5 indexed citations

11.

Schwarz, Lilian, Jean‐Baptiste Bachet, Aurélia Meurisse, et al.. (2022). Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).. Journal of Clinical Oncology. 40(16_suppl). 4134–4134. 21 indexed citations

12.

Sangro, Bruno, Junji Furuse, Jung‐Won Park, et al.. (2022). 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 33. S869–S870. 5 indexed citations

13.

Ychou, Marc, Emmanuelle Samalin, Éric Assenat, et al.. (2022). Sequential treatment with gemcitabine/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial.. Journal of Clinical Oncology. 40(16_suppl). TPS4191–TPS4191. 1 indexed citations

14.

Cassinotto, Christophe, Lauranne Piron, Serge Aho, et al.. (2020). Multimodal Percutaneous Thermal Ablation of Small Hepatocellular Carcinoma: Predictive Factors of Recurrence and Survival in Western Patients. Cancers. 12(2). 313–313. 28 indexed citations

15.

Riou, O., P. Fenoglietto, Thibault Mazard, et al.. (2019). Radiothérapie stéréotaxique hépatique : particularités cliniques et implications techniques, résultats. Quelle machine pour quelle situation ?. Cancer/Radiothérapie. 23(6-7). 636–650. 5 indexed citations

16.

Akce, Mehmet, José Luís Montero Álvarez, Éric Assenat, et al.. (2018). CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation. Annals of Oncology. 29. ix65–ix65. 13 indexed citations

17.

Boulin, Mathieu, Boris Guiu, Jean‐Pierre Pelage, et al.. (2016). Interventional oncology for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology. 40(5). 530–537. 9 indexed citations

18.

Assenat, Éric, et al.. (2009). La biopsie transrectale sous échographie endorectale des ganglions du mésorectum est-elle un examen de certitude lors du bilan d’extension locorégional des cancers du rectum ? Rapport d’un cas de faux-positif. Gastroentérologie Clinique et Biologique. 33(5). 451–455. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact